Roth Capital Has Bearish Forecast for CRDL Q1 Earnings

Cardiol Therapeutics Inc. (NASDAQ:CRDL) – Stock analysts at Roth Capital cut their Q1 2025 EPS estimates for shares of Cardiol Therapeutics in a research note issued to investors on Wednesday, April 16th. Roth Capital analyst J. Wittes now anticipates that the company will earn ($0.13) per share for the quarter, down from their prior estimate of ($0.09). The consensus estimate for Cardiol Therapeutics’ current full-year earnings is ($0.33) per share. Roth Capital also issued estimates for Cardiol Therapeutics’ Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.52) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.15) EPS and FY2026 earnings at ($0.57) EPS.

Cardiol Therapeutics (NASDAQ:CRDL) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01.

Other analysts also recently issued research reports about the stock. RODMAN&RENSHAW raised shares of Cardiol Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 28th. Rodman & Renshaw began coverage on shares of Cardiol Therapeutics in a research report on Tuesday, January 28th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a research note on Wednesday. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $8.40.

Cardiol Therapeutics Price Performance

Shares of Cardiol Therapeutics stock opened at $1.01 on Friday. The firm has a market cap of $83.44 million, a price-to-earnings ratio of -2.59 and a beta of 1.00. The stock’s 50-day moving average is $1.07 and its 200 day moving average is $1.40. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.49 and a quick ratio of 2.49. Cardiol Therapeutics has a one year low of $0.77 and a one year high of $3.12.

Hedge Funds Weigh In On Cardiol Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC bought a new position in shares of Cardiol Therapeutics in the third quarter valued at approximately $29,000. Lion Street Advisors LLC boosted its holdings in Cardiol Therapeutics by 12.6% during the 4th quarter. Lion Street Advisors LLC now owns 307,666 shares of the company’s stock worth $396,000 after acquiring an additional 34,385 shares during the last quarter. Jones Financial Companies Lllp bought a new stake in shares of Cardiol Therapeutics in the 4th quarter worth $25,000. Atria Investments Inc purchased a new stake in shares of Cardiol Therapeutics in the fourth quarter valued at about $174,000. Finally, Tejara Capital Ltd boosted its holdings in Cardiol Therapeutics by 75.9% during the fourth quarter. Tejara Capital Ltd now owns 3,115,437 shares of the company’s stock worth $3,988,000 after purchasing an additional 1,344,167 shares during the last quarter. Institutional investors and hedge funds own 12.49% of the company’s stock.

About Cardiol Therapeutics

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.